Altrenogest

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Altrenogest
Accession Number
DB11372
Description

Altrenogest, also known as allyltrenbolone, is a steroidal progestin that is widely used in veterinary medicine to suppress estrus in animals.

Type
Small Molecule
Groups
Vet approved
Structure
Thumb
Weight
Average: 310.437
Monoisotopic: 310.193280077
Chemical Formula
C21H26O2
Synonyms
  • 17-alpha-Allyl-estratriene-4,9,11,17-beta-ol-3-one
  • Allyl trenbolone
  • Allyltrenbolone
  • Altrenogestum
External IDs
  • A-35957
  • DRC 6246
  • R 2267
  • RU 2267
  • RU-2267

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabAltrenogest may decrease the anticoagulant activities of Abciximab.
AcenocoumarolAltrenogest may decrease the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidAltrenogest may decrease the anticoagulant activities of Acetylsalicylic acid.
AlteplaseAltrenogest may decrease the anticoagulant activities of Alteplase.
AncrodAltrenogest may decrease the anticoagulant activities of Ancrod.
AnistreplaseAltrenogest may decrease the anticoagulant activities of Anistreplase.
Antithrombin AlfaAltrenogest may decrease the anticoagulant activities of Antithrombin Alfa.
Antithrombin III humanAltrenogest may decrease the anticoagulant activities of Antithrombin III human.
ApixabanAltrenogest may decrease the anticoagulant activities of Apixaban.
ArdeparinAltrenogest may decrease the anticoagulant activities of Ardeparin.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrogens and derivatives
Alternative Parents
3-oxosteroids / 17-hydroxysteroids / Cyclohexenones / Tertiary alcohols / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
17-hydroxysteroid / 3-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Carbonyl group / Cyclic alcohol / Cyclic ketone / Cyclohexenone / Estrogen-skeleton / Hydrocarbon derivative
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
2U0X0JA2NB
CAS number
850-52-2
InChI Key
VWAUPFMBXBWEQY-ANULTFPQSA-N
InChI
InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/m1/s1
IUPAC Name
(1R,3aS,3bS,11aS)-1-hydroxy-11a-methyl-1-(prop-2-en-1-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,11aH-cyclopenta[a]phenanthren-7-one
SMILES
[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]

References

General References
  1. Machnik M, Hegger I, Kietzmann M, Thevis M, Guddat S, Schanzer W: Pharmacokinetics of altrenogest in horses. J Vet Pharmacol Ther. 2007 Feb;30(1):86-90. [PubMed:17217407]
  2. Kornheiser KM: Use of altrenogest in mares. J Am Vet Med Assoc. 1989 May 1;194(9):1150. [PubMed:2722647]
  3. Hodgson D, Howe S, Jeffcott L, Reid S, Mellor D, Higgins A: Effect of prolonged use of altrenogest on behaviour in mares. Vet J. 2005 May;169(3):322-5. [PubMed:15912604]
  4. Webel SK, Squires EL: Control of the oestrous cycle in mares with altrenogest. J Reprod Fertil Suppl. 1982;32:193-8. [PubMed:6962854]
  5. Soede NM, Bouwman EG, Langendijk P, van der Laan I, Kanora A, Kemp B: Follicle development during luteal phase and altrenogest treatment in pigs. Reprod Domest Anim. 2007 Jun;42(3):329-32. [PubMed:17506814]
  6. Sigler DH, Ericson DE, Gibbs PG, Kiracofe GH, Stevenson JS: Reproductive traits, lactation and foal growth in mares fed altrenogest. J Anim Sci. 1989 May;67(5):1154-9. [PubMed:2737975]
  7. Stevenson JS, Davis DL, Pollmann DS: Altrenogest and fat for summer breeding of primiparous sows. J Anim Sci. 1985 Aug;61(2):480-6. [PubMed:4044446]
  8. dos Santos JM, Wentz I, Bortolozzo FP, Barioni W Jr: Early-weaned sows: altrenogest therapy, estrus, ovulation, and reproductive performance. Anim Reprod Sci. 2004 Sep;84(3-4):407-13. [PubMed:15302382]
  9. Davis DL, Stevenson JS, Schmidt WE: Scheduled breeding of gilts after estrous synchronization with altrenogest. J Anim Sci. 1985 Mar;60(3):599-602. [PubMed:3988636]
  10. Rhodes MT, Davis DL, Stevenson JS: Flushing and altrenogest affect litter traits in gilts. J Anim Sci. 1991 Jan;69(1):34-40. [PubMed:2005028]
KEGG Drug
D02840
ChemSpider
8216634
RxNav
1314612
ChEMBL
CHEMBL1315492
ZINC
ZINC000004214784
Wikipedia
Altrenogest

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0301 mg/mLALOGPS
logP3.74ALOGPS
logP3.2ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)18.4ChemAxon
pKa (Strongest Basic)-0.18ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity95.46 m3·mol-1ChemAxon
Polarizability36.06 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on February 25, 2016 11:13 / Updated on June 12, 2020 10:53

44